Cargando…
A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA
PURPOSE: Breast cancer outcomes are impaired by both delays and disparities in treatment. This study was performed to assess their relationship and to provide a tool to predict patient socioeconomic factors associated with risk for delay. METHODS: The National Cancer Database was reviewed between 20...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747888/ https://www.ncbi.nlm.nih.gov/pubmed/35013916 http://dx.doi.org/10.1007/s10549-021-06460-9 |
_version_ | 1784630938116816896 |
---|---|
author | Verdone, Christopher G. Bayron, Jennifer A. Chang, Cecilia Wang, Chihsiung E. Sigurdson, Elin R. Aggon, Allison A. Porpiglia, Andrea Hill, Maureen V. Pronovost, Mary T. Bleicher, Richard J. |
author_facet | Verdone, Christopher G. Bayron, Jennifer A. Chang, Cecilia Wang, Chihsiung E. Sigurdson, Elin R. Aggon, Allison A. Porpiglia, Andrea Hill, Maureen V. Pronovost, Mary T. Bleicher, Richard J. |
author_sort | Verdone, Christopher G. |
collection | PubMed |
description | PURPOSE: Breast cancer outcomes are impaired by both delays and disparities in treatment. This study was performed to assess their relationship and to provide a tool to predict patient socioeconomic factors associated with risk for delay. METHODS: The National Cancer Database was reviewed between 2004 and 2017 for patients with non-metastatic breast cancer managed with upfront surgery. Times to treatment were measured from the date of diagnosis. Patient, tumor, and treatment factors were assessed with attention paid to sociodemographic variables. RESULTS: 514,187 patients remained after exclusions, with 84.3% White, 10.8% Black, 3.7% Asian, and Hispanics comprising 5.6% of the cohort. Medicaid and uninsured patients had longer mean adjusted time to surgery (≥ 46 days) versus private (36.7 days), Medicare (35.9 days), or other governmental insurance (39.8 days). After adjustment, Black race and Hispanic ethnicity were most impactful, adding 6.0 and 6.4 preoperative days, 10.9 and 11.5 days to chemotherapy, 11.1 and 9.1 days to radiation, and 12.5 and 8.9 days to endocrine therapy, respectively. Income, education, and insurance, among other factors, also affected delay. A nomogram, including race and sociodemographic factors, was created to predict the risk of preoperative delay. CONCLUSION: Significant disparities exist in timeliness of care for factors, including but not limited to, race and ethnicity. Although exact causes cannot be discerned, these data indicate population subsets whose intervals of care risk being longer than those specified by national quality standards. The nomogram created here may help direct resources to those at highest risk of incurring a treatment delay. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06460-9. |
format | Online Article Text |
id | pubmed-8747888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-87478882022-01-11 A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA Verdone, Christopher G. Bayron, Jennifer A. Chang, Cecilia Wang, Chihsiung E. Sigurdson, Elin R. Aggon, Allison A. Porpiglia, Andrea Hill, Maureen V. Pronovost, Mary T. Bleicher, Richard J. Breast Cancer Res Treat Preclinical Study PURPOSE: Breast cancer outcomes are impaired by both delays and disparities in treatment. This study was performed to assess their relationship and to provide a tool to predict patient socioeconomic factors associated with risk for delay. METHODS: The National Cancer Database was reviewed between 2004 and 2017 for patients with non-metastatic breast cancer managed with upfront surgery. Times to treatment were measured from the date of diagnosis. Patient, tumor, and treatment factors were assessed with attention paid to sociodemographic variables. RESULTS: 514,187 patients remained after exclusions, with 84.3% White, 10.8% Black, 3.7% Asian, and Hispanics comprising 5.6% of the cohort. Medicaid and uninsured patients had longer mean adjusted time to surgery (≥ 46 days) versus private (36.7 days), Medicare (35.9 days), or other governmental insurance (39.8 days). After adjustment, Black race and Hispanic ethnicity were most impactful, adding 6.0 and 6.4 preoperative days, 10.9 and 11.5 days to chemotherapy, 11.1 and 9.1 days to radiation, and 12.5 and 8.9 days to endocrine therapy, respectively. Income, education, and insurance, among other factors, also affected delay. A nomogram, including race and sociodemographic factors, was created to predict the risk of preoperative delay. CONCLUSION: Significant disparities exist in timeliness of care for factors, including but not limited to, race and ethnicity. Although exact causes cannot be discerned, these data indicate population subsets whose intervals of care risk being longer than those specified by national quality standards. The nomogram created here may help direct resources to those at highest risk of incurring a treatment delay. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-021-06460-9. Springer US 2022-01-11 2022 /pmc/articles/PMC8747888/ /pubmed/35013916 http://dx.doi.org/10.1007/s10549-021-06460-9 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Preclinical Study Verdone, Christopher G. Bayron, Jennifer A. Chang, Cecilia Wang, Chihsiung E. Sigurdson, Elin R. Aggon, Allison A. Porpiglia, Andrea Hill, Maureen V. Pronovost, Mary T. Bleicher, Richard J. A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA |
title | A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA |
title_full | A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA |
title_fullStr | A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA |
title_full_unstemmed | A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA |
title_short | A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA |
title_sort | tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the usa |
topic | Preclinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747888/ https://www.ncbi.nlm.nih.gov/pubmed/35013916 http://dx.doi.org/10.1007/s10549-021-06460-9 |
work_keys_str_mv | AT verdonechristopherg atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT bayronjennifera atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT changcecilia atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT wangchihsiunge atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT sigurdsonelinr atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT aggonallisona atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT porpigliaandrea atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT hillmaureenv atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT pronovostmaryt atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT bleicherrichardj atooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT verdonechristopherg tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT bayronjennifera tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT changcecilia tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT wangchihsiunge tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT sigurdsonelinr tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT aggonallisona tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT porpigliaandrea tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT hillmaureenv tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT pronovostmaryt tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa AT bleicherrichardj tooltopredictdisparitiesinthetimelinessofsurgicaltreatmentforbreastcancerpatientsintheusa |